0.82
-0.035(-4.07%)
Currency In USD
| Previous Close | 0.86 |
| Open | 0.87 |
| Day High | 0.87 |
| Day Low | 0.8 |
| 52-Week High | 1.19 |
| 52-Week Low | 0.54 |
| Volume | 552,266 |
| Average Volume | 475,176 |
| Market Cap | 9.6M |
| PE | -0.55 |
| EPS | -1.5 |
| Moving Average 50 Days | 0.85 |
| Moving Average 200 Days | 0.86 |
| Change | -0.04 |
If you invested $1000 in Biofrontera Inc. (BFRI) since IPO date, it would be worth $9.34 as of March 09, 2026 at a share price of $0.824. Whereas If you bought $1000 worth of Biofrontera Inc. (BFRI) shares 3 years ago, it would be worth $73.44 as of March 09, 2026 at a share price of $0.824.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026
GlobeNewswire Inc.
3 hours ago
WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will r
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
GlobeNewswire Inc.
12 hours ago
• Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz® PDT versus vehicle • 3-hour incubation regimen identified as the most promising protocol for further clinical development • Acne vulgaris represents a promisin
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable
GlobeNewswire Inc.
Feb 26, 2026 2:15 PM GMT
WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”), today announced that on February 23, 2026, the U.S.